• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease.在人类疾病的小鼠和非人类灵长类动物模型中，重组抗原诱导的皮肤利什曼病防护作用。
Infect Immun. 2001 Jun;69(6):4103-8. doi: 10.1128/IAI.69.6.4103-4108.2001.
2
Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice.用编码TSA/LmSTI1利什曼原虫融合蛋白的质粒DNA进行疫苗接种，可使易感的BALB/c小鼠对硕大利什曼原虫感染产生保护作用。
Infect Immun. 2002 Jun;70(6):2828-36. doi: 10.1128/IAI.70.6.2828-2836.2002.
3
Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis.用由T细胞抗原硫醇特异性抗氧化剂、硕大利什曼原虫应激诱导蛋白1和利什曼原虫延伸起始因子组成的多蛋白疫苗进行免疫接种可预防利什曼病。
Infect Immun. 2002 Aug;70(8):4215-25. doi: 10.1128/IAI.70.8.4215-4225.2002.
4
Testing of four Leishmania vaccine candidates in a mouse model of infection with Leishmania (Viannia) braziliensis, the main causative agent of cutaneous leishmaniasis in the New World.在感染巴西利什曼原虫（维安尼亚种）的小鼠模型中对四种利什曼原虫疫苗候选物进行测试，巴西利什曼原虫（维安尼亚种）是新世界皮肤利什曼病的主要病原体。
Clin Vaccine Immunol. 2007 Sep;14(9):1173-81. doi: 10.1128/CVI.00060-07. Epub 2007 Jul 11.
5
Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis.用编码利什曼原虫核小体组蛋白的质粒DNA混合物进行疫苗接种可提供针对小鼠皮肤利什曼病的保护作用。
Vaccine. 2004 Sep 28;22(29-30):3865-76. doi: 10.1016/j.vaccine.2004.04.015.
6
Evaluation of DNA/DNA and prime-boost vaccination using LPG3 against Leishmania major infection in susceptible BALB/c mice and its antigenic properties in human leishmaniasis.评价 LPG3 对易感 BALB/c 小鼠感染利什曼原虫的 DNA/DNA 和初免-加强免疫接种及其在人类利什曼病中的抗原性。
Exp Parasitol. 2011 Mar;127(3):627-36. doi: 10.1016/j.exppara.2010.12.007. Epub 2010 Dec 25.
7
Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4+ T cells.利什-111f，一种重组多蛋白疫苗，通过激发CD4+T细胞来预防内脏利什曼病。
Infect Immun. 2007 Sep;75(9):4648-54. doi: 10.1128/IAI.00394-07. Epub 2007 Jul 2.
8
Coencapsulation of CpG oligodeoxynucleotides with recombinant Leishmania major stress-inducible protein 1 in liposome enhances immune response and protection against leishmaniasis in immunized BALB/c mice.将CpG寡脱氧核苷酸与重组利什曼原虫主要应激诱导蛋白1共包封于脂质体中，可增强免疫反应，并保护免疫的BALB/c小鼠免受利什曼病感染。
Clin Vaccine Immunol. 2008 Apr;15(4):668-74. doi: 10.1128/CVI.00413-07. Epub 2008 Jan 30.
9
Comparative assessment of a DNA and protein Leishmania donovani gamma glutamyl cysteine synthetase vaccine to cross-protect against murine cutaneous leishmaniasis caused by L. major or L. mexicana infection.DNA 和蛋白质利什曼原虫γ-谷氨酰半胱氨酸合成酶疫苗对预防大疱性皮肤利什曼病或墨西哥利什曼原虫感染引起的小鼠皮肤利什曼病的交叉保护作用的比较评估。
Vaccine. 2012 Feb 8;30(7):1357-63. doi: 10.1016/j.vaccine.2011.12.067. Epub 2011 Dec 28.
10
Intranasal vaccination against cutaneous leishmaniasis with a particulated leishmanial antigen or DNA encoding LACK.使用颗粒状利什曼原虫抗原或编码LACK的DNA进行鼻内接种以预防皮肤利什曼病。
Infect Immun. 2004 Aug;72(8):4521-7. doi: 10.1128/IAI.72.8.4521-4527.2004.

引用本文的文献

1
Immunizing Mice with Influenza Virus-like Particles Expressing the Promastigote Surface Antigen Alleviates Inflammation in Footpad.用表达前鞭毛体表面抗原的流感病毒样颗粒免疫小鼠可减轻足垫炎症。
Vaccines (Basel). 2024 Jul 18;12(7):793. doi: 10.3390/vaccines12070793.
2
Engineering and design of promising T-cell-based multi-epitope vaccine candidates against leishmaniasis.针对利什曼病的有前景的基于 T 细胞的多表位疫苗候选物的工程和设计。
Sci Rep. 2023 Nov 8;13(1):19421. doi: 10.1038/s41598-023-46408-1.
3
Screening Novel Vaccine Candidates for by Combining Differential Proteomics and Immunoinformatics Analysis.通过差异蛋白质组学和免疫信息学分析筛选新型疫苗候选物。
Front Immunol. 2022 Jun 23;13:902066. doi: 10.3389/fimmu.2022.902066. eCollection 2022.
4
Anti-mitochondrial Tryparedoxin Peroxidase Monoclonal Antibody-Based Immunohistochemistry for Diagnosis of Cutaneous Leishmaniasis.基于抗线粒体硫氧还蛋白过氧化物酶单克隆抗体的免疫组织化学用于皮肤利什曼病的诊断
Front Microbiol. 2022 Feb 28;12:790906. doi: 10.3389/fmicb.2021.790906. eCollection 2021.
5
Vaccination in Leishmaniasis: A Review Article.《利什曼病疫苗接种：综述文章》。
Iran Biomed J. 2022 Jan 1;26(1):1-35. doi: 10.52547/ibj.26.1.35.
6
Effect of Prophylactic Vaccination with the Membrane-Bound Acid Phosphatase Gene of in the Murine Model of Localized Cutaneous Leishmaniasis.预防性接种膜结合酸性磷酸酶基因对小鼠局限性皮肤利什曼病模型的影响。
J Immunol Res. 2021 Apr 9;2021:6624246. doi: 10.1155/2021/6624246. eCollection 2021.
7
Non-human primates and immunity.非人灵长类动物与免疫
Cytokine X. 2020 Oct 12;2(4):100038. doi: 10.1016/j.cytox.2020.100038. eCollection 2020 Dec.
8
Allopurinol therapy provides long term clinical improvement, but additional immunotherapy is required for sustained parasite clearance, in -infected dogs.别嘌醇治疗可带来长期临床改善，但对于感染寄生虫的犬只，要实现寄生虫的持续清除，还需要额外的免疫治疗。
Vaccine X. 2019 Nov 20;4:100048. doi: 10.1016/j.jvacx.2019.100048. eCollection 2020 Apr 9.
9
Construction of a Novel DNA Vaccine Candidate encoding LmSTI1-PpSP42 Fusion Protein from and against Cutaneous Leishmaniasis.构建一种新型DNA疫苗候选物，其编码来自[具体来源1]和[具体来源2]的LmSTI1 - PpSP42融合蛋白，用于对抗皮肤利什曼病。
Rep Biochem Mol Biol. 2018 Oct;7(1):67-75.
10
Vaccination with whole-cell killed or recombinant leishmanial protein and toll-like receptor agonists against Leishmania tropica in BALB/c mice.用全细胞灭活或重组利什曼原虫蛋白和 Toll 样受体激动剂对 BALB/c 小鼠进行利什曼原虫热带株免疫接种。
PLoS One. 2018 Sep 24;13(9):e0204491. doi: 10.1371/journal.pone.0204491. eCollection 2018.

本文引用的文献

1
Identification and characterization of T cell-stimulating antigens from Leishmania by CD4 T cell expression cloning.通过CD4 T细胞表达克隆技术鉴定和表征来自利什曼原虫的T细胞刺激抗原。
J Immunol. 2001 Jan 1;166(1):498-505. doi: 10.4049/jimmunol.166.1.498.
2
Vervet monkeys vaccinated with killed Leishmania major parasites and interleukin-12 develop a type 1 immune response but are not protected against challenge infection.用灭活的硕大利什曼原虫寄生虫和白细胞介素-12接种的绿猴产生1型免疫反应，但对激发感染没有抵抗力。
Infect Immun. 2001 Jan;69(1):245-51. doi: 10.1128/IAI.69.1.245-251.2001.
3
Cell populations in lesions of cutaneous leishmaniasis of Leishmania (L.) amazonensis- infected rhesus macaques, Macaca mulatta.感染亚马逊利什曼原虫（Leishmania (L.) amazonensis）的恒河猴（Macaca mulatta）皮肤利什曼病病变中的细胞群体。
Mem Inst Oswaldo Cruz. 2000 Mar-Apr;95(2):209-16. doi: 10.1590/s0074-02762000000200012.
4
Subunit vaccination of mice against new world cutaneous leishmaniasis: comparison of three proteins expressed in amastigotes and six adjuvants.用亚单位疫苗接种小鼠预防新大陆皮肤利什曼病：对无鞭毛体中表达的三种蛋白质和六种佐剂的比较
Infect Immun. 2000 Mar;68(3):1328-36. doi: 10.1128/IAI.68.3.1328-1336.2000.
5
Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection.IgG1亚型的人源中和单克隆抗体可预防黏膜猿猴-人类免疫缺陷病毒感染。
Nat Med. 2000 Feb;6(2):200-6. doi: 10.1038/72309.
6
Antigen-specific humoral and cellular immune responses can be modulated in rhesus macaques through the use of IFN-gamma, IL-12, or IL-18 gene adjuvants.通过使用γ干扰素、白细胞介素-12或白细胞介素-18基因佐剂，可以调节恒河猴体内的抗原特异性体液免疫和细胞免疫反应。
J Med Primatol. 1999 Aug-Oct;28(4-5):214-23. doi: 10.1111/j.1600-0684.1999.tb00272.x.
7
Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis.在皮肤利什曼病灵长类动物模型中使用重组人白细胞介素-12和明矾作为佐剂的保护性免疫。
J Immunol. 1999 Oct 15;163(8):4481-8.
8
Cloning, characterization and serological evaluation of K9 and K26: two related hydrophilic antigens of Leishmania chagasi.杜氏利什曼原虫两种相关亲水性抗原K9和K26的克隆、特性鉴定及血清学评估
Mol Biochem Parasitol. 1999 Aug 20;102(2):249-61. doi: 10.1016/s0166-6851(99)00098-5.
9
Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran.在伊朗巴姆进行的单剂量灭活硕大利什曼原虫加卡介苗预防人源性皮肤利什曼病的随机疫苗试验。
Lancet. 1998 May 23;351(9115):1540-3. doi: 10.1016/S0140-6736(98)09552-X.
10
Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family.人类和小鼠对由一个多拷贝基因家族成员编码的新型利什曼原虫主要重组蛋白的免疫反应。
Infect Immun. 1998 Jul;66(7):3279-89. doi: 10.1128/IAI.66.7.3279-3289.1998.

在人类疾病的小鼠和非人类灵长类动物模型中，重组抗原诱导的皮肤利什曼病防护作用。

Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease.

作者信息

Campos-Neto A, Porrozzi R, Greeson K, Coler R N, Webb J R, Seiky Y A, Reed S G, Grimaldi G

机构信息

Infectious Disease Research Institute, Seattle, Washington 98104, USA.

出版信息

Infect Immun. 2001 Jun;69(6):4103-8. doi: 10.1128/IAI.69.6.4103-4108.2001.

DOI:10.1128/IAI.69.6.4103-4108.2001
PMID:11349082
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC98475/
Abstract

Leishmaniasis affects approximately 2 million people each year throughout the world. This high incidence is due in part to the lack of an efficacious vaccine. We present evidence that the recombinant leishmanial antigens LmSTI1 and TSA, which we identified and characterized previously, induce excellent protection in both murine and nonhuman primate (rhesus monkey) models of human cutaneous leishmaniasis. The remarkable protection induced by LmSTI1 and TSA in an animal model that is evolutionarily close to humans qualifies this antigen combination as a promising candidate subunit vaccine against human leishmaniasis.

摘要

利什曼病每年在全球影响约200万人。这种高发病率部分归因于缺乏有效的疫苗。我们提供的证据表明，我们之前鉴定和表征的重组利什曼原虫抗原LmSTI1和TSA，在人类皮肤利什曼病的小鼠和非人类灵长类动物（恒河猴）模型中均能诱导出极佳的保护作用。LmSTI1和TSA在与人类进化关系密切的动物模型中诱导出的显著保护作用，使这种抗原组合成为一种有前景的抗人类利什曼病亚单位疫苗候选物。